Meet the team behind the technology
Raphaël G. Ognar, MSC, MBACEO and Co-founder
Raphaël is a pharma/biotech executive with more than 25 years of commercial, drug development, product lifecycle, and strategy expertise. Throughout his career, he has developed extensive expertise in oncology/hematology, immuno-oncology, and cell therapy as a result of his recognized leadership skills in strategy and operations.
Besides fighting cancer, his passions are vintage wines, playing music in his family band, pushing himself rock climbing with his wife, and traveling the world with friends and family.
Raphaël has a master’s degree and a DEA (master’s) of physiology and neurosciences from the Universities of Bordeaux I and II and a master’s of business administration in strategic marketing and enterprise management from the Institut d’Administration des Entreprises (IAE) of Tours University.
Henri Bayle, PhDCTO/CDO and Co-founder
Hank has extensive experience in the development of new approaches to chimeric antigen receptor T (CAR-T) and CAR natural killer (CAR-NK) cell therapy from discovery to translation in the clinic from his work as a scientist and executive at Bellicum Pharmaceuticals. Previously he was an assistant professor at Baylor College of Medicine. He received his PhD in molecular biology from Princeton University and was a postdoctoral fellow at Stanford University School of Medicine.
Simon Wain-Hobson, DPhilCSO and Co-founder
Simon has published more than 230 papers in virology and cancer. Working with Luc Montagnier, he was first to sequence the genome of the AIDS virus HIV. He holds patents for the AIDS virus and 10 others. In addition to co-founding NKILT Therapeutics, he is a co-founder of Invectys, a US biotech company vaccinating against cancer. Simon received his DPhil in biochemistry from the University of Oxford and completed postdoctoral work in immunology at the Weizmann Institute. He was a tenured researcher, then professor, at the Pasteur Institute in Paris. He is an elected member of the European Molecular Biology Organization (EMBO), the Academia Europaea, and the US National Academy of Inventors. His accolades include Laureate, André Lwoff Prize; Laureate, Athena Prize, French Academy of Sciences; Officier de la Légion d’Honneur; and Officer of the Order of the British Empire.
Join us in engineering the future of cancer treatment
Interested in joining our innovative team led by experts in immunology, oncology, and cell therapy? We’d love to hear from you.Reach out about careers